KC1036

DRUG7 trials

Conditions

Advanced Solid TumorsDigestive System TumorsEsophageal Squamous Cell CarcinomaEsophageal Squamous Cell Carcinoma (ESCC)Ewing SarcomaHealthy SubjectsThymic Tumors

Phase 1

A Study of KC1036 in Patients with Advanced Solid Tumors

RecruitingNCT04387916

Beijing Konruns Pharmaceutical Co., Ltd.Advanced Solid Tumors

Start: 2020-09-04End: 2025-12-31Target: 207Updated: 2024-10-17

To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors

RecruitingNCT05260385

Beijing Konruns Pharmaceutical Co., Ltd.Digestive System Tumors

Start: 2022-01-24End: 2025-12-30Target: 133Updated: 2024-10-17

Phase 2

A Study of KC1036 in Patients with Advanced Thymic Tumors

RecruitingNCT05683886

Beijing Konruns Pharmaceutical Co., Ltd.Thymic Tumors

Start: 2023-02-22End: 2026-02-28Target: 30Updated: 2024-10-17

A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma

RecruitingNCT06564272

Beijing Konruns Pharmaceutical Co., Ltd.Ewing Sarcoma

Start: 2024-09-27End: 2028-04-01Target: 30Updated: 2024-08-23

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

RecruitingNCT07481058

Beijing Konruns Pharmaceutical Co., Ltd.Esophageal Squamous Cell Carcinoma (ESCC)

Start: 2025-12-12End: 2028-12-01Target: 60Updated: 2026-03-20

Phase 3

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

RecruitingNCT06194734

Beijing Konruns Pharmaceutical Co., Ltd.Esophageal Squamous Cell Carcinoma

Start: 2024-02-05End: 2027-12-30Target: 490Updated: 2024-03-07

Unknown Phase

A Food Effect Study of KC1036 in Healthy Subjects

CompletedNCT05265338

Beijing Konruns Pharmaceutical Co., Ltd.Healthy Subjects

Start: 2022-03-10End: 2022-03-23Updated: 2023-10-10

Related Papers

Efficacy and safety of second or further line KC1036 in patients with thymoma and thymic carcinoma: A multicenter, single-arm phase II trial.

Journal of Clinical Oncology2026-05-28

Algorithmic nudging for clinical trial participation: Autonomy and consent in the era of large language models

Research Ethics2026-05-25

KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.

Journal of Clinical Oncology2023-06-012 citations

First-in-human, phase I study of KC1036, a multiple kinase inhibitor, as a single agent in patients with advanced solid tumors.

Journal of Clinical Oncology2023-06-011 citations